France
Medical device market intelligence for France. Regulatory changes, competitor moves, and procurement trends.
Recent signals
A study in France will assess the safety and performance of the PerQseal® + vascular closure device in 20 patients.
A study on the complications from implantable devices in urinary incontinence and prolapse surgeries is ongoing.
The study evaluated CPAP treatment duration using the AL539 device in patients with Obstructive Sleep Apnea Syndrome.
The ATLAS medical device trial for low back pain was terminated, comparing it to a standard lumbar belt.
A study evaluated the skin tolerance of three class I medical masks over three days on normal and sensitive skin.
SAS ETABLISSEMENTS MAURICE MARLE is registered with the FDA under product code JWH.
A new BD micro needle aims to improve the tuberculosis intradermal skin test's administration and interpretation.
A study will assess connected BP devices for monitoring hypertension in patients starting cBTK inhibitors.
The study evaluates the clinical efficacy of the Maela® remote monitoring device in digestive oncology surgery postoperatively.
The BePoW device has completed evaluation for reliable wheelchair sitting posture measurement without MCPAA scale.
A portable medical device for breast cancer screening is being assessed in an active study.
A completed study in France assessed a probiotic medical device's effect on abdominal pain in IBS patients.
A clinical trial assesses the safety and efficacy of a RegenMatrix device combining PRP and HA for knee osteoarthritis.
A study completed by University Hospital, Rouen, evaluated the Herbst device for treating moderate obstructive sleep apnea.
A study evaluated glycemic control in in-patients using the Accu-Chek Inform system across three departments.
BIOMERIEUX SA has registered a medical device with product code JJH in the FDA database.
A multicenter trial is assessing the safety of the ProTool device for glioma tissue imprinting.
The study evaluates the cost-effectiveness of the Alfapump® device for refractory ascites in cirrhotic patients.
Exotec Dentaire's SEQUENCEUR RC TITANE BLEU CORPORIS is classified as Class IIa medical device.
M&A and divestitures are reshaping MedTech strategies, emphasizing market access for sustained growth and valuation.